Quick Search 
Drugs of Today
Register or sign in

  
 
  
Drugs Today 2020, 56(2): 125
ISSN 1699-3993
Copyright 2020 Clarivate Analytics
CCC: 1699-3993
DOI: 10.1358/dot.2020.56.2.3098156
 
 
Istradefylline: adenosine A2A receptor antagonist to reduce "OFF" time in Parkinson's disease
Paton, D.M.
 
 
Parkinson's disease (PD) is an extremely common degenerative disease with a progressive course. Unfortunately, the longer patients are treated with levodopa, the more likely they are to suffer from increasingly long periods of immobility or "OFF" time. For over 30 years Kyowa Kirin Co., Ltd. (formerly Kyowa Hakko Kirin Co., Ltd.) has been researching the possibility of finding drugs that affect adenosine receptors and that can be used successfully as additional drugs in the treatment of PD. Istradefylline is an adenosine A2A receptor antagonist that significantly reduces the "OFF" time and improves the motor function of patients with PD, as measured by the Unified Parkinson's Disease Rating Scale (UPDRS) Part III, while increasing the time without troublesome dyskinesia. It was approved for use in PD in Japan in 2013 and in the United States in 2019.


Full Text: PDF 
 
  



© Clarivate Analytics. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy